• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Lilly says weight loss drug cuts heart failure risk by 38% in trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 01, 2024 at 11:13: AM
via Trial results show Eli Lilly's (LLY.N) weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.
Shares of the drugmaker rose more than 3% in early trade.

article source
 




Top Bottom
Back
Quote